Altamira Therapeutics Announces Extension of Bentrio Distribution Agreement with Pharma Nordic to Include Sweden and Denmark
23 Agosto 2024 - 8:01AM
- Successful launch of Bentrio by Pharma Nordic AS in Norway in
2024
- Exclusive distribution agreement
extended to also include Sweden and Denmark
Altamira Therapeutics Ltd. (“Altamira” or the
“Company”) (Nasdaq:CYTO) today announced that its associate company
Altamira Medica Ltd. has agreed with its Norwegian partner Pharma
Nordic AS (“Pharma Nordic”) to extend the territory covered by
their exclusive distribution agreement for Bentrio® to Sweden and
Denmark. Following the successful launch in Norway earlier this
year, Pharma Nordic intends to introduce the Bentrio nasal spray
for the prevention and treatment of allergic rhinitis in these two
additional Scandinavian countries next year.
“We have been very pleased and impressed by
Pharma Nordic’s market launch activities and success in Norway,”
commented Thomas Meyer, Altamira Medica’s Chairman and CEO. “It is
therefore of mutual interest to expand in a next step the
geographical scope of our collaboration to include Sweden and
Denmark. We look forward to bringing Bentrio to patients in these
two other countries and to continuing to build the product together
with Pharma Nordic into one of the leading brands for allergic
rhinitis management in Scandinavia.”
“We received very favorable responses to Bentrio
from members of the medical community and allergic rhinitis
sufferers in Norway, showing a clear need for effective and safe
treatment alternatives” stated Bent Andreassen, CEO of Pharma
Nordic. “With its drug-free and preservative-free formulation, as
well as strong data on efficacy and tolerability, Bentrio is
uniquely positioned to address patients’ unmet needs. We are very
excited to continue the roll-out in Norway and to take Bentrio into
the Swedish and Danish markets, which share many things in common,
notably a passion for innovative health care
products.”
About Bentrio
Bentrio is an “over the counter” drug-free nasal
spray for personal protection against airborne allergens and, where
approved, against airborne viruses. Upon application into the nose,
Bentrio forms a protective gel layer on the nasal mucosa. This thin
film is designed to prevent the contact of airborne particles with
cells; in addition, the composition serves to bind such particles
and help with their discharge. The efficacy and safety of Bentrio
has been demonstrated in a total of four clinical trials, of which
the largest one (“NASAR” study) enrolled 100 patients suffering
from seasonal allergic rhinitis. In NASAR, participants
self-administered either Bentrio or saline nasal spray for two
weeks 3 times per day. The study showed a statistically significant
reduction in the mean daily reflective Total Nasal Symptom Score
(rTNSS) for Bentrio compared to saline (p = 0.013), as well as a
statistically highly significant improvement in health-related
quality of life (Rhinoconjunctivitis Quality of Life Questionnaire,
p < 0.001) and superior global ratings of efficacy by patients
and investigators alike (p < 0.001). In addition, Bentrio showed
good safety and tolerability, similar to saline controls, and fewer
Bentrio treated patients used relief medication and more of them
enjoyed symptom-free days compared to saline treatment. For more
information, visit: www.bentrio.com
About Altamira Therapeutics
Altamira Therapeutics (Nasdaq: CYTO) is
developing and supplying peptide-based nanoparticle technologies
for efficient RNA delivery to extrahepatic tissues (OligoPhore™ /
SemaPhore™ platforms). The Company currently has two flagship siRNA
programs using its proprietary delivery technology: AM-401 for KRAS
driven cancer and AM-411 for rheumatoid arthritis, both in
preclinical development beyond in vivo proof of concept. The
versatile delivery platform is also suited for mRNA and other RNA
modalities and made available to pharma or biotech companies
through out-licensing. In addition, Altamira holds a 49% stake
(with additional economic rights) in Altamira Medica AG, which
holds its commercial-stage legacy asset Bentrio®, an OTC nasal
spray for allergic rhinitis. Further, the Company is in the process
of partnering / divesting its inner ear legacy assets. Founded in
2003, Altamira is headquartered in Hamilton, Bermuda, with its main
operations in Basel, Switzerland. For more information, visit:
https://altamiratherapeutics.com/
About Pharma Nordic
Pharma Nordic AS, Aalsund, Norway holds licenses
in the Nordic countries on over-the-counter (OTC) medicines and
medical-technical equipment that are already on the world market or
are about to be launched on markets outside the Nordic countries.
For more information, visit: https://www.pharmanordic.no/
Forward-Looking Statements
This press release may contain statements that
constitute "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended.
Forward-looking statements are statements other than historical
facts and may include statements that address future operating,
financial or business performance or Altamira’s strategies or
expectations. In some cases, you can identify these statements by
forward-looking words such as "may", "might", "will", "should",
"expects", "plans", "anticipates", "believes", "estimates",
"predicts", "projects", "potential", "outlook" or "continue", or
the negative of these terms or other comparable terminology.
Forward-looking statements are based on management's current
expectations and beliefs and involve significant risks and
uncertainties that could cause actual results, developments and
business decisions to differ materially from those contemplated by
these statements. These risks and uncertainties include, but are
not limited to, the clinical utility of Altamira’s product
candidates, the timing or likelihood of regulatory filings and
approvals, Altamira’s intellectual property position and Altamira’s
financial position. These risks and uncertainties also include, but
are not limited to, those described under the caption "Risk
Factors" in Altamira’s Annual Report on Form 20-F for the year
ended December 31, 2023, and in Altamira’s other filings with the
Securities Exchange Commission (“SEC”), which are available free of
charge on the SEC’s website at: www.sec.gov. Should one or more of
these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results may vary materially
from those indicated. All forward-looking statements and all
subsequent written and oral forward-looking statements attributable
to Altamira or to persons acting on behalf of Altamira are
expressly qualified in their entirety by reference to these risks
and uncertainties. You should not place undue reliance on
forward-looking statements. Forward-looking statements speak only
as of the date they are made, and Altamira does not undertake any
obligation to update them in light of new information, future
developments or otherwise, except as may be required under
applicable law.
Investor Contact:
Hear@altamiratherapeutics.com
Altamira Therapeutics (NASDAQ:CYTO)
Gráfica de Acción Histórica
De Dic 2024 a Ene 2025
Altamira Therapeutics (NASDAQ:CYTO)
Gráfica de Acción Histórica
De Ene 2024 a Ene 2025
